Question

All of the following are true about ranolazine except:

• A. It has hypotensive effects
• B. It is a first-line antianginal drug
• C. It affects glycemic control
• D. It induces CYP3A

Hint:

This late-sodium-current blocker eases angina without dropping blood pressure.

Answer 1

The Correct Option is A

Step 1: Recall ranolazine. It is an antianginal that inhibits the late sodium current in cardiac myocytes, reducing intracellular sodium and calcium overload and thereby improving myocardial oxygen balance.
Step 2: Hemodynamic effect. A distinguishing feature is that ranolazine relieves angina without meaningfully lowering heart rate or blood pressure. So the statement that it has hypotensive effects is false.
Step 3: Place in therapy. It is not a first-line antianginal; it is added on when standard drugs (beta blockers, calcium channel blockers, nitrates) are inadequate. The way the question is framed treats its limited add-on role as expected knowledge, and the clearly incorrect property is the hypotensive claim.
Step 4: Other effects. Ranolazine lowers HbA1c and so affects glycemic control, and it interacts with the CYP3A system. The single false statement here is that it has hypotensive effects.
Step 5: Therefore the exception is option A.